Right Ventricle Has Normal Myofilament Function But Shows Perturbations in the Expression of Extracellular Matrix Genes in Patients With Tetralogy of Fallot Undergoing Pulmonary Valve Replacement.
Adolescent
Adult
Child
Collagen
/ analysis
Down-Regulation
Extracellular Matrix
/ genetics
Extracellular Matrix Proteins
/ isolation & purification
Female
Gene Expression
Gene Expression Profiling
/ methods
Heart Valve Prosthesis Implantation
Humans
Male
Middle Aged
Muscle Contraction
/ physiology
Myocytes, Cardiac
/ physiology
Myofibrils
/ physiology
Polymerase Chain Reaction
Pulmonary Valve
/ surgery
Pulmonary Valve Insufficiency
/ surgery
RNA, Messenger
/ metabolism
Small Leucine-Rich Proteoglycans
/ metabolism
Tetralogy of Fallot
/ genetics
Up-Regulation
Ventricular Function, Right
/ genetics
Young Adult
extracellular matrix
myofibril
pulmonary valve replacement
small leucine rich proteoglycan
tetralogy of Fallot
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
18 08 2020
18 08 2020
Historique:
pubmed:
18
8
2020
medline:
10
3
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Background Patients with repair of tetralogy of Fallot (rToF) who are approaching adulthood often exhibit pulmonary valve regurgitation, leading to right ventricle (RV) dilatation and dysfunction. The regurgitation can be corrected by pulmonary valve replacement (PVR), but the optimal surgical timing remains under debate, mainly because of the poorly understood nature of RV remodeling in patients with rToF. The goal of this study was to probe for pathologic molecular, cellular, and tissue changes in the myocardium of patients with rToF at the time of PVR. Methods and Results We measured contractile function of permeabilized myocytes, collagen content of tissue samples, and the expression of mRNA and selected proteins in RV tissue samples from patients with rToF undergoing PVR for severe pulmonary valve regurgitation. The data were compared with nondiseased RV tissue from unused donor hearts. Contractile performance and passive stiffness of the myofilaments in permeabilized myocytes were similar in rToF-PVR and RV donor samples, as was collagen content and cross-linking. The patients with rToF undergoing PVR had enhanced mRNA expression of genes associated with connective tissue diseases and tissue remodeling, including the small leucine-rich proteoglycans ASPN (asporin), LUM (lumican), and OGN (osteoglycin), although their protein levels were not significantly increased. Conclusions RV myofilaments from patients with rToF undergoing PVR showed no functional impairment, but the changes in extracellular matrix gene expression may indicate the early stages of remodeling. Our study found no evidence of major damage at the cellular and tissue levels in the RV of patients with rToF who underwent PVR according to current clinical criteria.
Identifiants
pubmed: 32805183
doi: 10.1161/JAHA.119.015342
pmc: PMC7660801
doi:
Substances chimiques
Extracellular Matrix Proteins
0
RNA, Messenger
0
Small Leucine-Rich Proteoglycans
0
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e015342Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/11/9/28705
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/16/3/32406
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/14/32397
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_1502/3
Pays : United Kingdom
Références
Circulation. 2008 Sep 30;118(14 Suppl):S182-90
pubmed: 18824753
J Thorac Cardiovasc Surg. 2001 Feb;121(2):344-51
pubmed: 11174741
J Mol Cell Cardiol. 2010 Nov;49(5):737-45
pubmed: 20615414
Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1421-1432
pubmed: 31181222
Cardiol Clin. 2002 Aug;20(3):395-404
pubmed: 12371008
Circulation. 2013 Feb 26;127(8):938-44
pubmed: 23439446
Circulation. 2004 Sep 14;110(11 Suppl 1):II153-7
pubmed: 15364855
FASEB J. 2016 Aug;30(8):2651-61
pubmed: 27080639
Circulation. 2018 May 29;137(22):2360-2370
pubmed: 29352073
Circ Heart Fail. 2009 Sep;2(5):456-64
pubmed: 19808376
Ann Thorac Surg. 1998 Aug;66(2):506-11
pubmed: 9725393
Circulation. 2007 Jul 31;116(5):545-51
pubmed: 17620511
Circ Heart Fail. 2013 Jan;6(1):136-44
pubmed: 23152488
Circulation. 2013 Oct 29;128(18):2016-25, 1-10
pubmed: 24056688
Arch Biochem Biophys. 2016 Jul 1;601:113-20
pubmed: 27036851
Circ Cardiovasc Imaging. 2017 Mar;10(3):
pubmed: 28292861
J Am Heart Assoc. 2020 Aug 18;9(16):e015342
pubmed: 32805183
FEBS J. 2013 May;280(10):2120-37
pubmed: 23331954
Lancet. 2000 Sep 16;356(9234):975-81
pubmed: 11041398
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H1-9
pubmed: 20472764
Matrix Biol. 2019 Jan;75-76:286-299
pubmed: 29337052
Circulation. 2012 Oct 9;126(15):1828-37
pubmed: 22972900
Nat Rev Nephrol. 2017 Apr;13(4):201-212
pubmed: 28163306
Biophys Rev. 2017 Aug;9(4):431-441
pubmed: 28808947
Circulation. 2017 Oct 31;136(18):1703-1713
pubmed: 29084778
Cardiovasc Res. 2008 Mar 1;77(4):649-58
pubmed: 18055579
J Mol Cell Cardiol. 2010 Mar;48(3):564-9
pubmed: 19524591
Circulation. 2013 Oct 22;128(17):1861-8
pubmed: 24065608
Basic Res Cardiol. 1994 Sep-Oct;89(5):397-410
pubmed: 7535519
Circ Res. 2009 Jan 2;104(1):87-94
pubmed: 19023132
Circulation. 2012 Feb 14;125(6):789-802
pubmed: 22261194
J Am Coll Cardiol. 1984 Apr;3(4):1013-8
pubmed: 6707338
J Clin Invest. 1996 Jul 1;98(1):167-76
pubmed: 8690789